Bluedop Medical secures £223.7k for non-invasive vascular diagnostic technology

Measuring blood flow and pressure for the screening of Peripheral Artery Disease is the core focus of Bluedop Medical Ltd, which has just raised £223.7k in new funding. Based in London, the company develops non-invasive ultrasound devices that provide healthcare professionals with diagnostic technology for the clinical assessment of patients with vascular conditions.

Founded in 2014, Bluedop Medical addresses the need for more efficient and pain-free vascular assessments. Its flagship product, BlueDop, offers a cuffless alternative to traditional Ankle Brachial Index screening methods. The technology is designed to simplify lower limb diagnostics in areas such as wound care, diabetic foot management, and tissue viability.

The current £223.7k raise follows several funding rounds completed over the last two years. In March 2026, the company raised £152.2k at a valuation of £8.8m. This followed a £150k raise in January 2026 and a £227.1k raise in October 2025. Earlier funding includes a £1.7m round in December 2023 and a £787.2k round in July 2024. The company previously reached a valuation of £9.2m in March 2023 following a £455.1k investment, and a £6.4m valuation in April 2022 after raising £500k.

Financial accounts for the year ended 31 December 2024 show that Bluedop Medical recorded a loss of £583.9k. The company currently employs 10 people at its London headquarters. The business provides its diagnostic tools to clinicians to improve patient outcomes and streamline the diagnostic process for vascular health.

The documentation for this latest capital injection was filed in May 2026, with an allotment date also recorded in May 2026. This funding contributes to the ongoing development of the company’s ultrasound technology and its application in clinical settings.